Related Experiment Video
Updated: Dec 30, 2025

Parasite Induced Genetically Driven Autoimmune Chagas Heart Disease in the Chicken Model
Published on: July 29, 2012
Chagas Disease: Chronic Chagas Cardiomyopathy
Insights
Chagas disease, caused by Trypanosoma cruzi, affects the heart and digestive systems years after infection. Current treatments for chronic Chagas cardiomyopathy are limited, necessitating further research for improved patient outcomes.
Area of Science:
- Infectious Diseases
- Cardiology
- Tropical Medicine
Background:
- Chagas disease (CD), caused by Trypanosoma cruzi, is a vector-borne infection endemic to South and Central America.
- Migration has increased the burden of CD in the United States and Europe.
- While the acute phase is often asymptomatic, the chronic phase can lead to significant organ damage, particularly cardiovascular and digestive complications.
Purpose of the Study:
- To review the pathophysiology and clinical manifestations of Chagas cardiomyopathy.
- To discuss current treatment strategies for Chagas disease and its chronic cardiac complications.
- To highlight the need for further research to improve clinical outcomes.
Main Methods:
- Literature review of studies on Chagas disease, Trypanosoma cruzi infection, and Chagas cardiomyopathy.
- Analysis of epidemiological data regarding the spread and impact of CD.
- Synthesis of information on current therapeutic approaches and ongoing research.
Main Results:
- Chagas cardiomyopathy is a leading cause of nonischemic cardiomyopathy in Latin America, affecting approximately 30% of infected individuals.
- Characteristic cardiac pathology includes diffuse myocarditis and focal fibrosis, predisposing to arrhythmias.
- Etiologic treatment is effective during the parasitic infection but lacks established efficacy in advanced chronic stages.
Conclusions:
- Chronic Chagas cardiomyopathy requires management similar to other nonischemic cardiomyopathies, but specific therapeutic advancements are needed.
- Further research is imperative to refine treatment protocols and improve the prognosis for patients with advanced Chagas disease.
- Ongoing studies aim to enhance clinical outcomes and develop more effective interventions for Chagas cardiomyopathy.
Abstract:
Chagas disease (CD) is a tropical vector-borne infection caused by the protozoan parasite Trypanosoma cruzi (T. cruzi), also known as American Trypanosomiasis. It is considered endemic in all South and Central America and in this past decades its becoming a burden particularly in the United States and Europe due to human migration. The vast majority of patients during the acute phase are asymptomatic, while chronic symptomatic phase appears years later, with around 30% progressing toward detectable organ damage affecting mainly the cardiovascular and digestive systems. Chagas cardiomyopathy is the leading cause of nonischemic cardiomyopathy (NICM) in Latin America and affects around 30% of infected patients. The foremost characteristics are a diffuse myocarditis with focal fibrosis, mainly located in the apex and basal segments of the posterior and inferior wall, leading to a highly arrhythmogenic disease. Treatment can be etiologic during the parasitic infection, without and established efficacy during the advanced chronic symptomatic phase. Chronic Chagas cardiomyopathy treatment consists in guided medical therapy for non-ischemic cardiomyopathy, but more studies are imperative to improve clinical outcomes, some of them already in progress, and hopefully soon refine treatment and recommendations.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy IV: Restrictive Cardiomyopathy
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
Myocarditis I: Introduction

